Phaseline

Targets › FKBP12

FKBP12 (Peptidyl-prolyl cis-trans isomerase FKBP1A): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 2; Infectious disease.

Keeps in an inactive conformation TGFBR1, the TGF-beta type I serine/threonine kinase receptor, preventing TGF-beta receptor activation in absence of ligand. Recruits SMAD7 to ACVR1B which prevents the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal. (UniProt, P62942)

Open in Phaseline: the race on FKBP12, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
F2GOlorofim (F901318)
Dihydroorotate dehydrogenase (quinone), mitochondrial inhibitor
FKBP12Phase 3Invasive Aspergillosis; Coccidioidal Meningitis–

Conditions

Invasive Aspergillosis (1) Coccidioidal Meningitis (1)

Modalities

small molecule (1)

Companies

F2G (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.